Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
about
Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyMethodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Abacavir/lamivudine combination in the treatment of HIV: a review.Population pharmacokinetics of abacavir in pregnant women.Current perspectives in HIV post-exposure prophylaxis.Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in JapanPharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Once-daily abacavir in place of twice-daily administration.Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Abacavir/lamividune combination in the treatment of HIV-1 infection: a review."One pill, once daily": what clinicians need to know about Atriplatrade mark.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTComparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.Abacavir hypersensitivity reaction: an update.Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.Efavirenz: a decade of clinical experience in the treatment of HIV.Causes and consequences of incomplete HIV RNA suppression in clinical trials.Abacavir and lamivudine combination.Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in GermanyResponse to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies.Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
P2860
Q27015850-A9ADAB6F-9C0C-41A0-B21A-8567D65BA4C1Q28473296-22459E83-A6E9-43F3-801B-9F1C5BE9E922Q33258171-330B74FA-568E-457A-8870-191C6448AAAAQ33715435-2C92348F-AD09-4A0F-A826-6F493A64EB98Q34299084-64C44946-8EA5-485C-94A7-51C4438E39B8Q34434815-FBA0447D-4AE4-4391-BBDF-63A885CDF8A1Q34503452-AE6B2328-58A8-4FE0-846F-ED13944BB75FQ34604408-9F061C19-6DCA-4410-982B-620AEAD63E06Q34713094-51DE404E-BC02-4242-89F4-BE81DEA8971AQ35233168-19B7D305-4A5D-4306-8707-20717931429CQ36097686-D636C13A-7BFB-4296-8F69-60C7876E318FQ36163198-FFB28224-19F5-4387-B620-D19B12CD4BB2Q36322100-6E0EB94C-2834-4CF3-8F95-1FA33A470046Q36653838-82454EA3-541D-4231-8EF3-0F96A0F52234Q36675417-76143511-7D99-43AC-A662-585A588A6093Q36823570-6A825A8E-B45A-46D9-AF26-8724321C4FC4Q36900010-C25D15E4-3B25-4457-B365-B07B11984C6FQ36919659-B5F974FE-8E5D-422D-B6E8-E61BEF85D6FEQ37077340-7871CB01-1357-4512-8CAD-03B94E2B3767Q37095697-98F82460-DD8B-47E8-93AD-8C270EA5FC17Q37144895-1DDF2A57-7540-4958-86B0-589DFA3B7CABQ37228748-C745A1D4-7FE6-4B30-B89A-BAFA673752BCQ37383949-94017137-9FC5-49C6-9362-61B5478903E6Q37631282-D5DAEE0B-1872-4B63-A52A-395A5CC6AC2FQ37636061-65999AC2-D089-4540-B011-70F71D7AE1D7Q37692734-B593E1DC-CCC9-4E3E-AFE8-5643896C0367Q41881433-A23D20FB-6536-4D45-BBF1-EFFD12901F8CQ42243458-D100B48B-BC66-461C-B98B-9B3B7FEE377EQ42422051-3C7E0668-0F28-4271-9BBD-1764F1E0DF47Q45864669-B6D4A197-8F70-4DE9-B009-0A1F13AD01AAQ46738435-514186B7-C28F-466E-B30D-D9385D419CFEQ51481656-9B7F42A9-5B3A-4483-BC98-5A7F61E4EF49Q58806292-0D9827CF-6107-4B96-92A0-281EC716630E
P2860
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Abacavir once or twice daily c ...... iretroviral Combination Study.
@en
Abacavir once or twice daily c ...... iretroviral Combination Study.
@nl
type
label
Abacavir once or twice daily c ...... iretroviral Combination Study.
@en
Abacavir once or twice daily c ...... iretroviral Combination Study.
@nl
prefLabel
Abacavir once or twice daily c ...... iretroviral Combination Study.
@en
Abacavir once or twice daily c ...... iretroviral Combination Study.
@nl
P2093
P1476
Abacavir once or twice daily c ...... tiretroviral Combination Study
@en
P2093
David N Gordon
Edwin DeJesus
Graeme J Moyle
Henry Zhao
Pedro Cahn
Steve A Castillo
Trevor R Scott
Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team
P304
P356
10.1097/01.QAI.0000147521.34369.C9
P407
P577
2005-04-01T00:00:00Z